A unique forum focusing on pursuing disease causation to foster the creation of targeted Microbiome-based therapeutics, biomarkers and diagnostics. Time: 8:30 am – 5:50 pm
Welcome to the 4th Microbiome Movement – Drug Development Summit Europe 2020. As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development.
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them.
Part of the foremost conference series for microbiome researchers in industry, the 4th Microbiome Movement – Drug Development Europe 2020 returns to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease, and help create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.
Across three days of case-studies, discussion and debates, learn how industry and academic leaders are understanding microbiome functionality across key therapeutic modalities, leveraging big data platforms to deduce causality, and overcoming regulatory, clinical and manufacturing hurdles to further accelerate their pipeline across new disease targets.
At this critical time, and as the microbiome community waits for the first clinical breakthrough, join your peers and unlock the potential of the human microbiome to create the next generation of microbiome-based therapeutics and diagnostic candidates of the future.
